 Eligible patients after signing informed consent will undergo study evaluation and then typed for acetylator phenotype before receive either 182 or 83 mg of hydralazine, and magnesium valproate at 30mgKg from day -7 to the end of chemoradiation external and brachytherapy. External beam radiation will be delivered by megavoltage equipment for a dose of 50gy 2Gy fraction from monday to friday concurrently with cisplatin at 40mgm2 for six weeks. Within one to two weeks, intracavitary brachytherapy low-dose rate, Cesium sources will be delivered to achieve at least 85Gy to point A. A punch biopsy from the primary tumor will be taken at entering the study and at day 8 of hydralazine and valproate treatment before the first dose of cisplatin and radiationto assess global gene expression profiling by microarray analysis. Blood samples will be taken to assess global DNA methylation, histone deacetylase activity and plasma levels of hydralazine and valproic acid. 